Clinical-stage biotechnology company Cynata Therapeutics completed the recruitment of participants for the Phase 3 SCUlpTOR1 clinical trial of CYP-004.
The enrollment surpassed the revised target sample size with 321 participants.
The trial, funded by the Australian Government National Health and Medical Research Council, will study the efficacy of CYP-004, an off-the-shelf iPSC-derived MSC product candidate designed for knee pain and osteoarthritis treatment.
The last participant visit in this trial is expected to occur around November 2025, with results anticipated in the first half of 2026.